Navigation Links
CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
Date:11/22/2013

New Haven, Conn. (PRWEB) November 22, 2013

CMDBioscience Inc., a pioneering innovator in peptide drug design and computational modeling, today announced the appointment of Tomi Sawyer, Ph.D., as the founding chair of its Scientific Advisory Board. Dr. Sawyer joins Victor Hruby, Ph.D., Bernhardt Trout, Ph.D., Benjamin Wolozin, Ph.D., and Yaoqi Zhou, Ph.D. as founding members of the Scientific Advisory Board.

Dr. Sawyer received his doctorate from the University of Arizona and is currently an adjunct professor at the University of Massachusetts (Department of Chemistry and Department of Biochemistry and Molecular Biology), the University of Massachusetts Medical School (Department of Cancer Biology), and Northeastern University (Center of Drug Discovery).

He was the founding chief scientific officer and senior vice president of drug discovery and innovative technologies at Aileron Therapeutics. Tomi has more than 30 years of pharmaceutical industry and biotech experience with multidisciplinary expertise in drug discovery and translational medicine with a focus on advancing peptides, peptidomimetics, and proteomimetics, natural products and small-molecules into the clinic. He is a former president of the American Peptide Society and founding editor-in-chief of Chemical Biology and Drug Design. Dr. Sawyer is credited with more than 320 publications and patents, and has presented nearly 200 keynote, plenary and invited lectures.

“We are delighted to have Tomi join the CMDBioscience team as the chair of our Scientific Advisory Board,” said Joseph Audie, chief executive officer of CMDBioscience. “Tomi has established a world-renowned reputation as both a scholar and leader in peptide drug discovery and brings an unrivaled wealth of expertise in peptide drug discovery and translational medicine to our Scientific Advisory Board.”

Dr. Sawyer’s responsibilities will include helping CMDBioscience to expand its cutting-edge and proprietary computational technology platform (CMDInventus) and forging strategic relationships with leading pharmaceutical and biotechnology companies.

“It’s an exciting time at CMDBioscience as we strive to be a formidable partner in peptide drug discovery,” said Dr. Audie. “The appointment of Tomi to the board further underscores our commitment to achieving the vision of transforming peptide drug discovery.”

“I’m very pleased to support the scientific and business vision of the CMDBioscience leadership team and board of directors,” said Dr. Sawyer. “The CMDBioscience drug design and computational modeling platform helps to accelerate peptide drug discovery and works with other key enabling technologies to advance future peptide therapeutics.”

About CMDBioscience
CMDBioscience is a computational biotechnology company that specializes in the development and application of proprietary computational methods to enable peptide drug discovery.

CMDBioscience has developed and enjoys exclusive access to CMDInventus, our proprietary computational peptide discovery platform. Using CMDInventus, CMDBioscience can help partner organizations efficiently identify novel peptide hits, understand the structural basis of target-peptide interactions, facilitate peptide hit-to-lead optimization and help solve a myriad of other peptide discovery problems.

CMDBioscience seeks to accelerate rational peptide discovery and increase value through collaborative peptide discovery partnerships. By working with CMDBioscience, our partners will gain privileged access to CMDInventus and our expertise, ultimately producing superior peptide-based discovery outcomes and increased value.

For more information on CMDBioscience, please visit http://www.cmdbioscience.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11362570.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
2. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
3. Convoy Therapeutics Appoints Clinical Advisory Board
4. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
5. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
6. ACTUS Appoints New Members to Its Management Team
7. Immune Design Appoints Stephen R. Brady Chief Business Officer
8. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
9. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
10. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
11. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... PMG Research is pleased to announce its participation ... Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on how ... and bring them closer to the patient. Clinical Trial Collaborations also will present an ...
(Date:3/27/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is now offering a ... consumers who want to have their DarioHealth products reimbursed ... alliance agreements with partners across the U.S. who will ... approved, will supply and bill the customer,s insurance for ...
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
Breaking Biology News(10 mins):